rheumatoid arthritis

Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Fierce Biotech
Gilead Sciences
JAK inhibitors
filgotinib
rheumatoid arthritis
Flag link:
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Yahoo/Zacks.com
Amgen
ABP 710
JNJ
Merck
Remicade
biosimilars
rheumatoid arthritis
Flag link:
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
Yahoo/Motley Fool
AbbVie
Huimra
Upadacitinib
rheumatoid arthritis
Flag link:
AbbVie to submit upadacitinib to FDA after 5th trial win
AbbVie to submit upadacitinib to FDA after 5th trial win
Fierce Pharma
AbbVie
Upadacitinib
rheumatoid arthritis
FDA
JAK inhibitors
Flag link:
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Xconomy
Eli Lilly
Incyte
FDA
rheumatoid arthritis
olumiant
baricitinib
Flag link:
Gilead and Alphabet's Verily to Collaborate on Research in Immunological and Molecular Drivers of Inflammatory Diseases
Gilead and Alphabet's Verily to Collaborate on Research in Immunological and Molecular Drivers of Inflammatory Diseases
CP Wire
Gilead Sciences
Verily
Immunoscape
lupus
rheumatoid arthritis
inflammatory bowel disease
Flag link:
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
CP Wire
AbbVie
rheumatoid arthritis
Upadacitinib
clinical trials
Flag link:
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
Xconomy
Eli Lilly
FDA
advisory panels
rheumatoid arthritis
baricitinib
Incyte
Flag link:
Big Week Ahead for Eli Lilly: Here's What to Look For
Big Week Ahead for Eli Lilly: Here's What to Look For
Motley Fool
Eli Lilly
earnings
FDA
Incyte
olumiant
rheumatoid arthritis
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Incyte
TG Therapeutics
Cara Therapeutics
CR845
opioids
ublituximab
leukemia
olumiant
rheumatoid arthritis
Flag link:
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms
Xconomy
Eli Lilly
baricitinib
olumiant
rheumatoid arthritis
Flag link:
With study success, AbbVie's arthritis hopeful looks to be a safer bet
With study success, AbbVie's arthritis hopeful looks to be a safer bet
Biopharma Dive
AbbVie
rheumatoid arthritis
Upadacitinib
Humira
clinical trials
Flag link:
Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment
Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment
Fierce Biotech
Alivio Therapeutics
hydrogels
rheumatoid arthritis
Flag link:
Positive momentum for biotech Incyte
Positive momentum for biotech Incyte
GoinPharma
Inctye
olumiant
baricitinib
rheumatoid arthritis
Flag link:
This 3D-printed device analyzes tissue cells from rheumatoid arthritis
This 3D-printed device analyzes tissue cells from rheumatoid arthritis
Medical Design and Outsourcing
3D printing
rheumatoid arthritis
diagnostics
Flag link:
$690M deal in peril after Lilly ends mid-stage studies
$690M deal in peril after Lilly ends mid-stage studies
Biopharma Dive
Eli Lilly
clinical trials
rheumatoid arthritis
Btk inhibitors
Hanmi Pharmaceutical
LY3337641/HM71224
Flag link:
Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact
Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact
Endpoints
Eli Lilly
rheumatoid arthritis
Hanmi Pharmaceutical
clinical trials
Flag link:
Why AbbVie's Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
Why AbbVie's Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
Market Realist
AbbVie
Upadacitinib
rheumatoid arthritis
Flag link:
Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug
Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug
BioPharma Dive
AbbVie
rheumatoid arthritis
Upadacitinib
ABT-494
Flag link:
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Yahoo/Reuters
Pfizer
biosimilars
JNJ
Remicade
Ifixi
rheumatoid arthritis
Crohn's Disease
Flag link:

Pages